Research & Development
Day Zero awarded $8.2 million in CARB-X funding
Day Zero is developing diagnostic tests that use genome sequencing and machine-learning algorithms to rapidly identify pathogens and their antibacterial-resistance profiles.
October 20, 2022
T2 Biosystems inks distribution agreement in Baltic region
Under the terms of the agreement, the company will sell T2Dx Instruments, along with T2Bacteria, T2Candida, and T2Resistance panels, through an undisclosed distributor.
September 22, 2022
Guidance for antibiotics, diagnostics use in an epidemic
In a statement published Wednesday in Infection Control & Hospital Epidemiology, SHEA provided strategies for hospitals and healthcare personnel to improve antibiotic prescribing when they encounter new infectious disease outbreaks.
September 14, 2022
Method shown to rapidly identify children’s UTIs
The method uses urinalysis results and other variables to predict UTIs and delivers answers before the two to three days needed for culture results.
July 26, 2022
Vela launches new PCR test for detecting urinary tract infection
The test, called PathoKey MP UTI ID and AMR PCR, is currently for research use only, the company said. It allows for the in vitro detection and categorization of 14 pathogens that cause urinary tract infections and 14 antimicrobial resistance genes that block five antibiotics.
May 18, 2022
Day Zero Diagnostics closes $21M funding round
The company is developing sequencing-based diagnostic technologies that can identify both the species and the antibiotic-resistance profile of a bacterial pathogen within hours.
February 10, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
‘Good’ cholesterol worse for some adults: NIH study
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Hologic launches on-demand molecular testing in Europe
Novodiag features real-time polymerase chain reaction and microarray capabilities that allow for multiple pathogens to be identified from a single sample, Hologic said. Its CE-marked IVD test menu includes assays for gastrointestinal infection, antibiotic resistance, and SARS-CoV-2.
October 5, 2021
DNA testing speeds pneumonia diagnoses in COVID-19 patients
Developed at Addenbrooke's Hospital in Cambridge, U.K., with Public Health England, the polymerase chain reaction (PCR) test screens for 52 different pathogens that may cause respiratory illness in intensive care patients.
January 14, 2021
Bruker launches microbe test kit following FDA clearance
Rapid sepsityper identification is crucial for the care of critically ill patients in order to reduce turnaround time for disease-specific treatment, noted Dr. Wolfgang Pusch, executive vice president of microbiology and diagnostics at Bruker. The new test kit can identify microbial species once a blood culture system has detected growth, but it does not test for resistance of antibiotic susceptibility.
January 3, 2021
Firm developing rapid gonorrhea test wins $19M prize
Visby Medical won the prize for its patient-side, disposable, molecular polymerase chain reaction (PCR) diagnostic device that detects Neisseria gonorrhoeae as well as markers of drug resistance. The device is a palm-sized, single-use, disposable device that detects N. gonorrhoeae and can determine whether the bacteria is susceptible to a single-dose antibiotic.
August 5, 2020
LexaGene to unveil rapid multipathogen genetic test this fall
The product, which is currently being manufactured, aims to deliver reference-quality molecular testing data at the point of care. It screens samples for up to 27 different targets at once, looking for pathogens and antimicrobial resistance factors. Results are delivered in about an hour, according to the company.
July 14, 2020
Inflammatix gets $32M infusion for HostDx rapid POC tests
Based in Burlingame, CA, Inflammatix is developing blood and nasal swab tests for the detection of infections and antibiotic resistance. Its platform is informed by machine-learning algorithms and gene expression patterns to identify bacterial and viral infections, and it yields results in 30 minutes or less, according to the company.
January 9, 2020
Page 1 of 2